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Abstract
Background: The aims of this retrospective study were to evaluate laparoscopic triage of patients
with advanced ovarian cancer towards primary surgery or neoadjuvant chemotherapy, and to
analyze outcome according to the treatment.
Methods: Between January 2001 and December 2006, 55 patients with stage III – IV ovarian
cancer underwent diagnostic laparoscopy. Primary surgery was performed when complete
cytoreduction was considered feasible, while the other patients received neoadjuvant
chemotherapy (platinum-based combination with taxanes) and interval surgery. All the patients
received adjuvant chemotherapy.
Results: Patients treated with neoadjuvant chemotherapy (n = 29) had a higher mean body mass
index (P = 0.048), higher serum CA 125 levels (P = 0.026), and more metastases (P = 0.045) than
patients treated with primary surgery (n = 26). In patients treated with primary surgery, complete
cytoreduction and a residual tumour size ≤ 2 cm were obtained in respectively 54% and 77% of
cases. Complete cytoreduction was achieved in respectively 100% and 33% of cases when primary
surgery was performed by an oncologic gynaecologist and by a non-oncologic gynaecologist (P =
0.002). Interval surgery yielded complete cytoreduction and a residual tumour size ≤ 2 cm in
respectively 73% and 85% of cases. With a median follow-up of 24 months (range 7 – 78 months),
the survival rates after primary surgery and interval surgery were 61% and 66% respectively.
Conclusion: Diagnostic laparoscopy is useful for identifying patients with stage III/IV ovarian
cancer who qualify for primary cytoreduction. Surgeon experience was a determining factor for the
success of complete cytoreduction.
Background
The extent of cytoreductive surgery and the amount of
residual tumour are the most important survival determi-
nants in patients with advanced ovarian cancer [1,2]. In
order to increase the rate of complete or optimal debulk-
ing and to limit peri-operative morbidity, neoadjuvant
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chemotherapy with interval cytoreduction has emerged as
an alternative to primary surgery. This delayed strategy
does not seem to compromise survival [3,4]. However,
although neoadjuvant chemotherapy is an acceptable
alternative for patients with unresectable disease, Bristow
et al have stressed that survival appears to be poorer after
initial chemotherapy than after successful up-front cytore-
ductive surgery [5]. Hence, the main issue is how to eval-
uate the resectability of stage III/IV ovarian cancer.
Despite improvements in CT, MR and PET scan, and in
tumour markers, the resectability of intraperitoneal dis-
ease remains difficult to judge [6-8]. Several predictive
models have been proposed, based on clinical findings
(ascites, etc.), imaging, and the CA125 serum level, but
false-positive rates range from 5% to 37% and surgical
evaluation is therefore crucial [6-8].
Diagnostic laparoscopy was first proposed as a second-
look procedure for guiding subsequent treatment, but it
proved to be less reliable than laparotomy [9]. Diagnostic
laparoscopy was then used to assess the resectability of
advanced ovarian cancer, with a view to either primary
cytoreductive surgery or neoadjuvant chemotherapy with-
out impacting on its delay [10]. In patients whose disease
appears resectable on laparoscopy, optimal debulking
rates range from 67% to 96% [10-15].
The aims of this longitudinal retrospective study were to
examine whether, in patients with stage III/IV ovarian
cancer, diagnostic laparoscopy can select those with a
high likelihood of complete cytoreduction, and to com-
pare the operative procedures, recurrence rates and sur-




Between January 2001 and December 2006, 72 patients
with strong evidence of advanced ovarian cancer (FIGO
stage III – IV) underwent surgical exploration in our
department. The inclusion criteria were good nutritional
status, and no contraindication to surgery.
Preoperative evaluation included general and gynaecolog-
ical examination, pelvic sonography, serum CA 125 assay,
routine blood tests, EKG, chest radiography and com-
puted abdominopelvic tomography (CT).
Fifty-five patients had diagnostic laparoscopy to assess the
possibility of complete debulking surgery (defined as no
visible residual tumour). Laparoscopy has been progres-
sively introduced since 2001 and is now considered as a
standard of care in our institution. Patients were informed
that surgery included a preliminary laparoscopic
approach to assess resectability. Therefore, informed con-
sent was obtained for the whole surgery itself.
Surgical technique
A longitudinal midline incision of approximately 15 mm
was made just above or below the umbilicus. The rectus
sheath was identified and incised longitudinally. The per-
itoneum was opened and a blunt 10-mm disposable tro-
car was gently introduced into the peritoneal cavity under
visual and digital control. A second 5-mm trocar was then
inserted under direct visual control into the midline,
about 40 to 50 mm above the pubic arch. An attempt was
made to inspect the entire abdominal cavity systemati-
cally, by using atraumatic forceps: the ovaries, fallopian
tubes, uterus, pelvic peritoneum, serosa and mesentery of
the large and small bowel, liver surface, paracolic gutters
and diaphragm were carefully examined. When necessary,
an additional 5-mm trocar was used to facilitate dissec-
tion of adhesions with scissors and bowel manipulation.
Biopsy specimens of the ovaries or metastatic nodules or
peritoneal surface were used for extemporaneous frozen
section to confirm the diagnosis of ovarian cancer. At the
end of the laparoscopic procedure, all the layers of incised
abdomen were closed separately with resorbable sutures
at level of the umbilical trocar site, to avoid trocar metas-
tases.
The procedures were performed by seven surgeons with
adequate laparoscopic training; three were experts in
gynaecologic oncology and four were non-oncologic
gynaecologic surgeons. Twenty-six patients were treated
by the gynaecologic oncologists (47%).
Study design
After complete laparoscopic exploration of the pelvis and
abdomen, the patients either underwent laparotomy and
primary cytoreductive surgery through a midline xifo-
pubic incision, or received neoadjuvant chemotherapy
followed by interval debulking surgery and subsequent
adjuvant chemotherapy.
Patients had primary cytoreductive surgery only when
complete macroscopic cytoreduction (absence of visible
residual tumour) was considered feasible. Primary
debulking surgery included total hysterectomy, bilateral
salpingo-oophorectomy, total infragastric omentectomy,
appendectomy, peritonectomy (limited to the pelvis, the
paracolic gutters, or focally in the anterolateral diaphrag-
matic area), spleen resection when necessary, and rectos-
igmoid resection when indicated. Pelvic, common iliac,
and infrarenal paraaortic lymphadenectomy was part of
the standard operation for patients with good medical sta-
tus at the end of debulking surgery and with complete
macroscopic cytoreduction. Adjuvant chemotherapy
always consisted of carboplatin and paclitaxel adminis-BMC Cancer 2009, 9:171 http://www.biomedcentral.com/1471-2407/9/171
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tered every 3 weeks. Six chemotherapy cycles were
planned.
Neoadjuvant chemotherapy was indicated when the sur-
geon judged that optimal cytoreduction could not be
achieved. The reasons for choosing neoadjuvant chemo-
therapy instead of primary debulking surgery included
factors related to the patient herself (comorbidity,
increased anaesthetic risk) and to the extent of the disease
(findings during diagnostic open laparoscopy). Surgical
findings influencing the decision to opt for neoadjuvant
chemotherapy included extensive visceral peritoneal dis-
ease (diffuse superficial involvement of organs such as the
small bowel, mesentery, large bowel, liver and gallblad-
der), and extensive involvement of the upper abdomen
(diaphragm and liver, or hepatic pedicle).
Neoadjuvant chemotherapy always consisted of a plati-
num-based combination with taxanes, administered every
3 weeks. The number of chemotherapy cycles depended
on the response, based on clinical examination, serum CA
125 assay and CT scan. The patients were then referred for
standard debulking, as described above. The size of the
residual tumour at the end of surgery was recorded. After
debulking, chemotherapy combining carboplatin and
paclitaxel was subsequently administered to all patients.
No attempt was made to compare the predictive value of
imaging methods and laparoscopy.
Demographics, the disease stage and the histological type
were first compared between the neoadjuvant chemother-
apy and primary surgery groups. Categorical variables
were compared with Fisher's exact test or the chi-square
test, depending on the sample size. Quantitative data were
compared with the Mann-Whitney test. The surgical
response, recurrence rate and survival were then com-
pared. Disease-free survival curves after diagnosis (first
surgical procedure) were calculated according to the Kap-
lan-Meier method, and compared with the log-rank test.
Significance was assumed at a P value < 0.05.
Results
Characteristics of the patients undergoing primary surgery 
and neoadjuvant chemotherapy
Among the 55 patients referred to our department for
laparoscopic evaluation of stage III – IV ovarian cancer, 26
patients underwent primary surgery after diagnostic lapar-
oscopy. Histological diagnosis was based on the salpingo-
oophorectomy specimen in all 26 patients.
Twenty-nine patients received neoadjuvant chemother-
apy, because of severe comorbidity in 3 cases and exten-
sive disease in 26 cases. Suboptimal resection was
predicted on the basis of extensive peritoneal disease
involving the upper abdomen and mesentery and/or
requiring multiple bowel resection in all 26 patients. The
histological diagnosis was based on peritoneal biopsy in
17 patients (59%), ovarian biopsy in 8 (27%), salpingo-
oophorectomy in 3 (10%), and partial omentectomy in 1
(3%). The three patients with severe comorbidity died one
month after the first cycle of neoadjuvant chemotherapy
and were excluded from the study population because
interval surgery could not be performed. The causes of
death were not related to the toxicity of the chemotherapy
but to bowel obstruction in two patients and pulmonary
embolism in one patient.
The characteristics of the 52 remaining patients are sum-
marized in Table 1. Patients treated with neoadjuvant
chemotherapy had a higher body mass index (BMI), a
higher serum CA 125 level, and more metastases than
patients treated with primary surgery.
Results of primary surgery after diagnostic laparoscopy 
(table 2)
Residual tumours smaller than 2 cm (optimal surgery)
were obtained in 20 cases (77%). Fourteen patients (54%)
had no macroscopic residue (i.e. complete cytoreduction)
after primary surgery. The surgeon's expertise influenced
the probability of complete cytoreduction: cytoreduction
was complete in 100% of cases when debulking surgery
was performed by an oncologic gynaecologist, compared
to only 33% of cases when performed by a non-oncologic
gynaecologist (P = 0.002). Primary surgery was combined
with lymphadenectomy in 17 patients with residual
tumours ≤ 1 cm.
The adjuvant chemotherapy regimen was carboplatin and
paclitaxel in all 26 patients. The median number of adju-
vant chemotherapy cycles was 6 (range, 1–9). Five
patients died before completing the 6 cycles. Three
patients with incomplete response to chemotherapy
(abnormal CA 125 levels at the end of the 6 cycles) under-
went 3 additional cycles of the same regimen.
In one patient treated with primary surgery, a metastasis
occurred 5 months after the procedure at the insertion site
of the ancillary trocar. This patient had a residual tumour
> 2 cm after surgery and was considered chemoresistant.
Surgical treatment of patients receiving neoadjuvant 
chemotherapy
The median interval between diagnostic laparoscopy and
the beginning of neoadjuvant chemotherapy was 11 days
(range: 1–30). The neoadjuvant chemotherapy regimens
were carboplatin-paclitaxel for 23 patients (88%), carbo-
platin-docetaxel for 1 patient (4%), and oxaliplatin-
docetaxel for 2 patients (8%). The median number of neo-
adjuvant chemotherapy cycles was 4 (range, 3–8). FifteenBMC Cancer 2009, 9:171 http://www.biomedcentral.com/1471-2407/9/171
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patients (58%) received 3 or 4 cycles of neoadjuvant
chemotherapy. All 15 of these patients responded after 3
cycles, based on clinical examination, the serum CA 125
level, and abdominopelvic CT. Eleven patients (42%)
who did not respond after 3 cycles received 6 cycles or
more. All 11 of these patients underwent interval surgery,
when the disease was considered stable (6 patients) or in
regression (5 patients).
The response to neoadjuvant chemotherapy was judged
from the tumour burden at interval surgery. In 17 patients
(65%) the largest tumour was smaller than 2 cm after neo-
adjuvant chemotherapy. Twelve of these patients had
required only 3 or 4 cycles of neoadjuvant chemotherapy.
No macroscopic tumour residue was found in 6 cases
(after 3 cycles in 4 cases). The remaining 9 patients (35%)
had tumours ranging from 3 to 13 cm after 3 cycles (n =
3) or more than 6 cycles (n = 6) of neoadjuvant chemo-
therapy.
The results of interval surgery are summarized in table 2.
Residual tumours of less than 2 cm were obtained in 22
cases (85%). Complete cytoreduction was obtained in 19
cases (73%). The surgeon's expertise did not influence the
probability of complete cytoreduction; cytoreduction was
complete in 60% and 81% of cases when debulking sur-
gery was performed by an oncologic gynaecologist and a
non-oncologic gynaecologist, respectively.
No trocar metastases occurred in patients treated with
neoadjuvant chemotherapy.
After debulking, chemotherapy combining carboplatin
and paclitaxel was administered to 20 patients until 6
cycles. For 5 patients with incomplete response to 6 cycles
of carboplatin paclitaxel, a second line chemotherapy
with gemcitabin or topotecan was administered. The
remaining patient died post-operatively from the evolu-
tion of the disease before receiving the first post-operative
cycle of chemotherapy.






Median age (y, range) 62 (21 – 88) 60 (26 – 81) NS
Median parity (range) 1 (0 – 7) 1 (0 – 4) NS
Median BMI * (range) 24 (19 – 31) 22 (16 – 30) 0.048
BMI ≥ 30 (%) 2 (8) 2 (8) NS
Post-menopausal (%) 21 (81) 22 (85) NS
Cancer history ** (%)
Familial 6 (23) 10 (38) NS
Personal 0 2 (8)
Familial and personal 2 (8) 1 (4)
None 18 (69) 13 (50)
Stage (%)
IIIB 1 (4) 3 (12) 0.045
IIIC 20 (77) 23 (88)
IV 5 (19) 0
Histology (%)
Serous 16 (61) 14 (54) NS
Mucinous 1 (4) 0
Endometrioid 6 (23) 7 (27)
Clear cells 0 4 (15)
Undifferentiated 2 (8) 1 (4)
Other 1 (4) 0
Grade (%)
12  ( 8 ) 4  ( 1 6 ) NS
2 13 (50) 11 (42)
3 9 (34) 11 (42)
Unknown 2 (8) 0
Emboli (%) 6 (23) 7 (27) NS
Pleural effusion (%) 3 (12) 0 NS
Pre-operative CA125 (%)
≤ 500 U/ml 8 (31) 16 (61) 0.026
> 500 U/ml 18 (69) 10 (39)
* BMI: Body mass index; ** Only breast, uterus, ovarian and colon cancer were considered.BMC Cancer 2009, 9:171 http://www.biomedcentral.com/1471-2407/9/171
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The median number of chemotherapy cycles was 8 (range,
4–16). The median number of post-operative chemother-
apy cycles was 4 (range, 2–8).
Survival after primary and interval surgery
Survival probabilities were calculated according to the
treatment strategy. The median follow-up was 24 months
(range 7 – 78). Including the three patients who died
before interval surgery, the survival rates were 66% and
61%, respectively, among patients who had neoadjuvant
chemotherapy and primary surgery.
In patients with complete cytoreduction (no or micro-
scopic residual tumours), the respective median disease-
free survival times after primary surgery and after neoad-
juvant chemotherapy followed by interval surgery were 50
months and 27 months (Figure 1). In patients with no
residual disease, the median disease-free survival times
were 50 months and 33 months respectively (P = 0.04). In
patients with macroscopic residual tumours, the median
disease-free survival times after primary surgery and after
neoadjuvant chemotherapy followed by interval surgery
were 25 months and 22 months, respectively. There was
no significant difference in disease-free survival between
patients who had primary surgery and those who had
interval surgery, except in the subgroup of patients with
no macroscopic and microscopic residual tumours.
Discussion
This study shows that diagnostic laparoscopy can reliably
identify patients with advanced-stage ovarian cancer who
are likely to have optimal cytoreduction during primary
surgery. When diagnostic laparoscopy showed unresecta-
ble disease, the rate of optimal cytoreduction during inter-
val surgery following neoadjuvant chemotherapy was
similar to that achieved during primary surgery in patients
with resectable disease. However, survival tended to be
better after complete cytoreduction during primary sur-
gery than during interval surgery.
Half of the patients, all of whom had stage III ovarian can-
cer, were considered to be good candidates for primary
cytoreductive surgery on the basis of diagnostic laparos-
copy. These results are in keeping with previous studies
underlying the contribution of laparoscopy to evaluate
resectability [12,15]. Using extensive visceral peritoneal
metastases, extensive involvement of the upper abdomen,
extensive small bowel involvement and multiple liver
metastases as criteria of unresectability, Angioli et al
reported that 61% of patients were considered operable
on the basis of diagnostic laparoscopy [12]. In our series,
54% of patients who were considered operable on the
basis of diagnostic laparoscopy had complete macro-
scopic cytoreduction, and respectively 69% and 77% of
patients had optimal cytoreduction defined by a residual





Total hysterectomy (%) 22 (85) 23 (88)
Bilateral salpingo-oophorectomy (%) 25 (96) 26 (100)
Omentectomy (%) 24 (92) 24 (92)
Rectosigmoid resection (%) 5 (19) 8 (31)
Multiple bowel resection (%) 1 (4) 1 (4)
Cytology of ascites (%)
Positive 8 (42) 14 (54)
Negative 11 (58) 12 (46)
ND 70
Lymphadenectomies (%) 13 (50) 17 (65)
Median lymph nodes removed (range) 25 (10 – 50) 23 (4 – 50)
Median lymph nodes involved (range) 1 (0 – 4) 2 (0 – 14)
Median ratio involved/removed (range) 4 (0 – 36) 7 (0 – 57)
Complete cytoreduction 19 (73) 14 (54)
Residual tumour (%)
≤ 1 cm 2 (8) 4 (15)
1.1 – 2 cm 1 (4) 2 (8)
> 2 cm 4 (15) 6 (23)
Location of residual tumour* (%)
Pelvis 2 (15) 3 (19)
Upper abdomen 6 (46) 6 (37.5)
Peritoneal, extensive 4 (31) 6 (37.5)
Retroperitoneal 1 (8) 1 (6)
* Some patients had more than one location.BMC Cancer 2009, 9:171 http://www.biomedcentral.com/1471-2407/9/171
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tumour size of ≤ 1 cm and ≤ 2 cm. These results are better
than those of previous laparotomic studies, in which opti-
mal cytoreduction (< 2 cm residual tumour) was achieved
in 35% to 50% of patients [4,14]. The use of diagnostic
laparoscopy to identify candidates for primary cytoreduc-
tive surgery among patients with advanced-stage ovarian
cancer is controversial. In a multicenter study of 77
patients with stage III-IV ovarian cancer, Vergote et al
reported that diagnostic laparoscopy selected 28 patients
for primary surgery, and that cytoreductive surgery was
optimal (< 0.5 cm largest residual tumour size) in 79% of
these 28 patients [10]. These results may appear better
than ours, but it should be noted that, contrary to us, the
latter authors used clinical and radiological findings to
select patients for laparoscopy. Angioli et al [12] reported
complete cytoreductive surgery (no residual tumour) in
96% of patients whose diagnostic laparoscopy showed
tumor resectability, while Fagotti et al reported optimal
cytoreduction (residual tumour ≤ 1 cm) in 67% of such
patients [15].
In our study, the surgeons with expertise in gynaecologic
oncology achieved complete cytoreduction during pri-
mary surgery in 100% of cases. In previous reports, opti-
mal cytoreduction during primary surgery was achieved in
20% to 90% of cases, according to the experience of the
surgeon and the centre [16-19]. Although the definition of
optimal cytoreduction remains debatable, it should be
noted that the cut-off of 1 cm residual disease commonly
used does not reflect major differences in terms of progno-
sis. Indeed, in a retrospective review of 1895 patients with
stage III ovarian cancer carried out by the Gynecologic
Oncology Group (GOG), patients with 0.1 to 1.0 cm and
> 1.0 cm residual disease had a 2 – 2.5 fold increased risk
of recurrence and death compared with patients with no
macroscopic residual disease [20].
The main issue in advanced-stage ovarian cancer is how to
select candidates for primary cytoreductive surgery and
therefore to avoid unnecessary laparotomy with subopti-
mal cytoreduction that would delay chemotherapy. Given
the re-growth of tumour cells between chemotherapy
cycles, cytoreductive surgery should be maximally benefi-
cial in patients with complete cytoreduction or limited
tumour residues [21,22]. Previous studies have suggested
that voluminous ascites was associated with suboptimal
cytoreductive surgery [23,24]. Bristow et al proposed a
score based on radiological variables such as peritoneal
thickening, peritoneal implants > 2 cm, bowel mesentery
tumours > 2 cm, suprarenal lymph nodes > 1 cm, omental
extension to the spleen, pelvic sidewall involvement, and
hydroureter to identify unresectable disease [7]. Models
based on clinical and CT findings as well as serum tumour
markers have also been developed [5], but their false-neg-
ative rates range from 5% to 37% [6-9]. Moreover, cross-
validation of these predictive algorithms also failed to
identify good candidates for neoadjuvant chemotherapy.
Indeed, 62% to 86% of patients considered to have had
suboptimal surgery had optimal cytoreduction [5]. In
contrast, diagnostic laparoscopy can accurately identify
patients who may benefit from primary complete cytore-
duction. A laparoscopy-based score for predicting surgical
outcome was recently developed by Fagotti et al on the
basis of a pilot study [15]. Omental cake, peritoneal carci-
nomatosis, diaphragmatic carcinomatosis, mesenteric
retraction, bowel and/or stomach infiltration, and liver
metastases were each assigned a value of 2. In the final
model, a predictive index score of ≥ 8 had a specificity of
100%, a positive predictive value of 100% and a negative
predictive value of 70% for prospectively identifying
patients with residual tumours after debulking surgery.
External validation by other teams is required to confirm
the usefulness of diagnostic laparoscopy in this setting,
and to develop a scoring system to predict resectability.
Interval surgery allowed complete cytoreduction in 73%
of our patients with unresectable disease at diagnostic
laparoscopy. Our rate of optimal cytoreductive surgery is
in keeping with that reported elsewhere with neoadjuvant
chemotherapy (62% to 94%) [12,25,26]. Likewise, Angi-
oli et al reported complete debulking in 80% of cases [12],
although their intention-to-treat data were not reported.
After reintegration of nine patients excluded from interval
surgery, the rate of complete cytoreduction during interval
Survival probability among patients with no or microscopic  residual tumour after primary (---) and interval (—) surgery  (P = 0.28) Figure 1
Survival probability among patients with no or 
microscopic residual tumour after primary (---) and 
interval (—) surgery (P = 0.28).BMC Cancer 2009, 9:171 http://www.biomedcentral.com/1471-2407/9/171
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surgery fell to 59%. In our study, the frequency of intesti-
nal resection was the same in patients undergoing primary
surgery as in those undergoing interval surgery with neo-
adjuvant chemotherapy. In the same way, the number of
positive lymph nodes and the ratio of positive to total
nodes did not differ between the two groups, suggesting
that neoadjuvant chemotherapy was not effective on
lymph node involvement. Although Morice et al found no
difference in overall and disease-free survival between
patients undergoing primary cytoreductive surgery and
those receiving neoadjuvant chemotherapy and cytore-
ductive interval surgery, interval surgery was associated
with less morbidity [26]. Likewise, Chan et al found that
their patients' overall quality of life and functional status
improved after neoadjuvant chemotherapy [27]. How-
ever, in a recent meta-analysis, Bristow et al found that
neoadjuvant chemotherapy was associated with poorer
survival relative to initial surgery [5]. This can be
explained by the inclusion of non-randomized studies in
this meta-analysis [5]. Moreover, patients receiving the
neoadjuvant chemotherapy had clinically worse disease
than those chosen to undergo primary surgery and should
have been expected to have worse survival. Although no
significant difference was observed in our study, probably
owing to a small sample size and short follow-up, survival
tended to be better after primary surgery than after inter-
val surgery among women who had complete cytoreduc-
tion. Probably due to the same limits of the study, no such
difference was observed between the patients with resid-
ual tumours after primary and interval surgery. However,
in the meta-analysis of Bristow et al, patients who were
referred for neoadjuvant chemotherapy were considered
unresectable solely on the basis of physical examination,
CT findings and/or serum marker levels, possibly exclud-
ing some patients who would have qualified for poten-
tially complete primary cytoreduction [5].
Conclusion
Our results support the use of diagnostic laparoscopy for
identifying patients with advanced-stage ovarian cancer
who are likely to benefit from primary surgery with com-
plete cytoreduction, and the importance of the primary
surgery being performed by an oncologic gynaecologist.
Pending the results of the EORTC trial comparing neoad-
juvant chemotherapy with primary cytoreduction
(EORTC 55971), laparoscopy should be used to identify
patients qualifying for complete primary cytoreductive
surgery.
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